DRUG-ELUTING COATING ON SHOCKING COIL OF TACHY LEAD AND METHODS RELATED THERETO

• US 20070299491A1
• Filed: 06/22/2006
• Published: 12/27/2007
• Est. Priority Date: 06/22/2006
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Borgaonkar, Harshad, Pederson, Michael J.
• Application Number:
  US11/425,889
• Publication Number:
  US 20070299491A1
• Time in Patent Office: Days
• US Class Current: 607/120
• CPC Class Codes: A61N 1/056 Transvascular endocardial electrode systems
• CPC Class Codes: A61N 1/0563 specially adapted for defibrillation or cardioversion
• CPC Class Codes: A61N 1/0568 with drug delivery
• CPC Class Codes: A61N 1/0573 chacterised by means penetrating the heart tissue, e.g. helix needle or hook

Abstract

A tachy lead includes a lead body extending from a lead proximal end portion to a lead distal end portion and having an intermediate portion therebetween, one or more tissue sensing/stimulation electrodes disposed along the lead body, one or more terminal connections disposed along the lead proximal end portion. The lead further includes one or more conductors contained within the lead body extending between the tissue sensing/stimulation electrodes and the terminal connections, a porous drug-eluting coating disposed onto at least a portion of the lead body and/or sensing/stimulation electrodes, wherein the drug-eluting coating comprises porous polytetrafluoroethylene (PTFE), a biodegradable polymer and one or more drugs.

Claims

1. A tachy lead comprising:

a lead body extending from a lead proximal end portion to a lead distal end portion, and having an intermediate portion therebetween;

one or more tissue sensing/stimulation electrodes disposed along the lead body;

one or more terminal connections disposed along the lead proximal end portion;

one or more conductors contained within the lead body extending between the tissue sensing/stimulation electrodes and the terminal connections;

a porous drug-eluting coating disposed onto at least a portion of the lead body and/or sensing/stimulation electrodes; and

wherein the porous drug-eluting coating comprises;

porous polytetrafluoroethylene (PTFE);

a biodegradable polymer; and

one or more drugs.

2. The tachy lead of claim 1, wherein at least one of the one or more tissue sensing/stimulation electrodes is a defibrillation shocking coil electrode.

3. The tachy lead of claim 1, wherein the one or more tissue sensing/stimulation electrodes is selected from the group of anode, cathode, defibrillation shocking coil electrode, or combinations thereof.

4. The tachy lead of claim 1, wherein the rate of drug-elution from the porous drug-eluting coating may be controlled.

5. The tachy lead of claim 1, wherein the biodegradable polymer comprises polylactic acid and its derivatives, polyglycolic acid and its derivatives, polycaprolactum, copolymers of lactic acid, glycolic acid and caprolactum, polyethylene glycol, hyaluranic acid and its derivatives, phoshorylcholine, polyvinylpyrrolidone (PVP) or combinations thereof.

6. The tachy lead of claim 1, wherein the one or more drugs comprise an anti-inflammatory, anti-proliferative, anti-arrhythmic, anti-migratory, anti-neoplastic, antibiotic, anti-restenotic, anti-coagulation, anti-clotting, anti-thrombogenic or immunosuppressive agent, or an agent that promotes healing and/or re-endothelialization or combinations thereof.

7. The tachy lead of claim 1, wherein the one or more drugs comprise paclitaxel, clobetasol, rapamycin (sirolimus), everolimus, tacrolimus, actinomycin-D, dexamethasone, mometasone furoate, hyaluronic acid, vitamin E, mycophenolic acid, cyclosporins, beclomethasone, their derivatives, analogs, salts or combinations thereof.

8. A tachy lead comprising:

a lead body extending from a lead proximal end portion to a lead distal end portion, and having an intermediate portion therebetween;

one or more tissue sensing/stimulation electrodes disposed along the lead body;

one or more defibrillation shocking coil electrodes;

one or more terminal connections disposed along the lead proximal end portion;

one or more conductors contained within the lead body extending between the tissue sensing/stimulation electrodes and the terminal connections;

a porous drug-eluting coating disposed onto at least a portion of the lead body and/or the one or more defibrillation shocking coil electrodes; and

wherein the porous drug-eluting coating comprises;

porous polytetrafluoroethylene (PTFE);

a biodegradable polymer; and

one or more drugs.

9. A lead system comprising:

one or more tachy leads, each tachy lead comprising;

a lead body;

one or more electrodes disposed along the lead body;

a porous drug-eluting coating disposed onto at least a portion of the lead body and/or electrodes;

wherein the porous drug-eluting coating comprises;

porous polytetrafluoroethylene (PTFE);

a biodegradable polymer; and

one or more drugs; and

an implantable medical device, electrically coupled to the one or more tachy leads.

10. The lead system of claim 9, further comprising an energy source coupled to the implantable medical device.

11. The lead system of claim 9, wherein the rate of drug-elution from the porous drug-eluting coating may be controlled.

12. The lead system of claim 9, wherein the at least one of the one or more electrodes is a defibrillation shocking coil electrode.

13. The lead system of claim 9, wherein the biodegradable polymer comprises polylactic acid and its derivatives, polyglycolic acid and its derivatives, polycaprolactum, copolymers of lactic acid, glycolic acid and caprolactum, polyethylene glycol, hyaluranic acid and its derivatives, phoshorylcholine, polyvinylpyrrolidone (PVP) or combinations thereof.

14. The lead system of claim 9, wherein the one or more drugs comprise an anti-inflammatory, anti-proliferative, anti-arrhythmic, anti-migratory, anti-neoplastic, antibiotic, anti-restenotic, anti-coagulation, anti-clotting, anti-thrombogenic or immunosuppressive agent, or an agent that promotes healing and/or re-endothelialization or combinations thereof.

15. The lead system of claim 9, wherein the one or more drugs comprise paclitaxel, clobetasol, rapamycin (sirolimus), everolimus, tacrolimus, actinomycin-D, dexamethasone, mometasone furoate, hyaluronic acid, vitamin E, mycophenolic acid, cyclosporins, beclomethasone, their derivatives, analogs, salts or combinations thereof.

16. A method of manufacturing a lead, the method comprising:

forming a tachy lead; and

disposing a porous drug-eluting coating on all or a portion of the lead;

wherein the drug-eluting coating comprises;

porous polytetrafluoroethylene (PTFE)

a biodegradable polymer; and

one or more drugs.

17. The method of claim 16, wherein disposing the porous drug-eluting coating on all or a portion of the lead includes disposing on all or a portion of one or more electrodes.

18. The method of claim 17, wherein at least one of the one or more electrodes is a defibrillation shocking coil electrode.

19. The method of claim 16, wherein disposing a porous drug-eluting coating includes spraying, dipping, sputtering or brushing.

20. The method of claim 16, wherein disposing a porous drug-eluting coating includes injecting with a syringe in-situ.

21. The method of claim 16, wherein the biodegradable polymer comprises polylactic acid and its derivatives, polyglycolic acid and its derivatives, polycaprolactum, copolymers of lactic acid, glycolic acid and caprolactum, polyethylene glycol, hyaluranic acid and its derivatives, phoshorylcholine, polyvinylpyrrolidone (PVP) or combinations thereof.

22. The method of claim 16, wherein the one or more drugs comprise an anti-inflammatory, anti-proliferative, anti-arrhythmic, anti-migratory, anti-neoplastic, antibiotic, anti-restenotic, anti-coagulation, anti-clotting, anti-thrombogenic or immunosuppressive agent, or an agent that promotes healing and/or re-endothelialization or combinations thereof.

23. The method of claim 16, wherein the one or more drugs comprise paclitaxel, clobetasol, rapamycin (sirolimus), everolimus, tacrolimus, actinomycin-D, dexamethasone, mometasone furoate, hyaluronic acid, vitamin E, mycophenolic acid, cyclosporins, beclomethasone, their derivatives, analogs, salts or combinations thereof.